View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Research Reports
November 17, 2016

Report: Myelofibrosis market to grow at the compound annual growth rate of 6.4% by 2025

The myelofibrosis market is projected to increase from $545.2m last year to $1.02bn by 2025, according to a report by GlobalData.

The myelofibrosis market is projected to increase from $545.2m last year to $1.02bn by 2025, according to a report by GlobalData.

Titled 'OpportunityAnalyzer: Myelofibrosis – Opportunity Analysis and Forecasts to 2025', the report provides forecast for the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK and Japan.

Growth in the myelofibrosis market is projected to be mainly driven by the launch of pipeline agents such as Gilead’s momelotinib, Promedior’s PRM-151, and Johnson & Johnson/Geron’s imetelstat. Increase in the incidence of myelofibrosis, and use of drugs targeting splenomegaly and constitutional symptoms are some of the other reasons responsible for the growth.

"Imetelstat may face difficulties in market penetration due to late market entry and a high level of toxicity demonstrated in earlier clinical trials."

Incyte/Novartis’ Jakafi is currently the only drug approved for the treatment of the splenomegaly and constitutional symptoms associated with myelofibrosis. No other approved drug is available for patients who have become unresponsive to Jakafi. Momelotinib and imetelstat, scheduled to be launched next year and 2021 respectively, are expected to address this gap.

Imetelstat, a first-in-class telomerase inhibitor, however, may face difficulties in market penetration due to late market entry and a high level of toxicity demonstrated in earlier clinical trials, opines James Beggs, GlobalData’s Analyst covering oncology and haematology. Sales of the drug in 2025 are estimated to be $21.2m, which is 2% of the myelofibrosis market in the 7MM.

The other drug under development, PRM-151, is expected to be more successful due to its positive anti-fibrotic effects and capability to reduce dependency on treatments for anaemia, splenomegaly, and constitutional symptoms. The drug is expected to capture significant market share by fulfilling these unmet needs.

Despite the emergence of the new drugs, Jakafi is expected to retain its leading position in the market, holding more than 50% of the market share in 2025. Jakafi has the advantages of being first-to-market and having proven long-term efficacy and safety profile.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology